Abstract
Monoclonal antibody engineered T lymphocyte selectivity for human ovarian cancer: Preclinical and clinical results : [formula omitted]1, S.H. Goey 2, J.W. Gratama 1, G. Stoter 2. Department of Immunology 1 and Medical Oncology 2, Dr. Daniel den Hoed Cancer Center, Groene Hilledijk 301, Rotterdam, The Netherlands
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
